Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib

Lian, Xiangyao; Zhu, Cuimin; Lin, Huiyun; Gao, Zhengxing; Li, Guangxin; Zhang, Ninggang; Cao, Bangwei; Kang, Yan

doi:10.1042/bsr20194167

Cited by 8 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EGFR TKIs enhance the radioactivity of bladder cancer cells by synergistically blocking EGFR and HER2 [ 68 ]. As to esophageal cancer, pyrotinib sensitized HER2-positive esophageal cancer cells to radiotherapy by inhibiting HER2 phosphorylation, inducing G0/G1 phase arrest, thus reducing EMT and DNA repair [ 69 ].…”

Section: Intracranial Radiotherapy Combined With Targeted Therapy For...mentioning

confidence: 99%

Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases

Yang

Ren

et al. 2023

Eur J Med Res

View full text Add to dashboard Cite

Radiotherapy and targeted therapy are essential treatments for patients with brain metastases from human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, the combination of radiotherapy and targeted therapy still needs to be investigated, and neurotoxicity induced by radiotherapy for brain metastases has also become an important issue of clinical concern. It remained unclear how to achieve the balance of efficacy and toxicity with the application of new radiotherapy techniques and new targeted therapy drugs. This article reviews the benefits and potential risk of combining radiotherapy and targeted therapy for HER2-positive breast cancer with brain metastases.

show abstract

Section: Intracranial Radiotherapy Combined With Targeted Therapy For...mentioning

confidence: 99%

Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases

Yang

Ren

et al. 2023

Eur J Med Res

View full text Add to dashboard Cite

show abstract

“…It starts the process by inducing the expression of a mesenchymal phenotype and eventually leads to progression and dissemination [ 20 , 62 , 73 ]. The HER2 / ERBB2 / NEU gene, amplified in 15–35% of BC cancers [ 74 , 75 ], encodes a RTK that activates EMT [ 76 ] as well as the repair of radiation-induced DNA damage [ 77 ]. Another RTK, AXL, was reported to activate EMT and HR even in TNBC cell lines [ 78 ].…”

Section: Dynamic Changes In Dna Damage Responses Are Intricately Link...mentioning

confidence: 99%

Circulating Tumor Cells in Breast Cancer Patients: A Balancing Act between Stemness, EMT Features and DNA Damage Responses

Heitmeir

Deniz

Janni

et al. 2022

Cancers

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) traverse vessels to travel from the primary tumor to distant organs where they adhere, transmigrate, and seed metastases. To cope with these challenges, CTCs have reached maximal flexibility to change their differentiation status, morphology, migratory capacity, and their responses to genotoxic stress caused by metabolic changes, hormones, the inflammatory environment, or cytostatic treatment. A significant percentage of breast cancer cells are defective in homologous recombination repair and other mechanisms that protect the integrity of the replication fork. To prevent cell death caused by broken forks, alternative, mutagenic repair, and bypass pathways are engaged but these increase genomic instability. CTCs, arising from such breast tumors, are endowed with an even larger toolbox of escape mechanisms that can be switched on and off at different stages during their journey according to the stress stimulus. Accumulating evidence suggests that DNA damage responses, DNA repair, and replication are integral parts of a regulatory network orchestrating the plasticity of stemness features and transitions between epithelial and mesenchymal states in CTCs. This review summarizes the published information on these regulatory circuits of relevance for the design of biomarkers reflecting CTC functions in real-time to monitor therapeutic responses and detect evolving chemoresistance mechanisms.

show abstract

“…Systemic chemotherapy plays a vital role in the treatment of advanced patients, whose median survival time is less than one year [4]. At present, the targeted drugs used in the treatment of EC are only targeted at HER2 or vascular endothelial growth factor [5][6][7]. The therapeutic impact of conventional treatment plus targeted medications is still not ideal.…”

Section: Introductionmentioning

confidence: 99%

Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study

Wang

Jin

Cheng

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

This study is aimed at assessing the sintilimab-based regimens’ safety and efficacy for advanced esophageal cancer (EC) treatment in the real world. Cases of advanced EC treated with sintilimab-based regimens in the Anyang Tumor Hospital between 1 January 2020 and 1 August 2021 were retrospectively examined. Progression-free survival (PFS), overall survival (OS), disease control rate (DCR), objective response rate (ORR), and adverse events (AEs) were evaluated. Among the 50 included patients, the median PFS was 11.3 months (95% CI: 5.0-17.6 months), and the 1-year PFS rate was 49.2%. The median OS was not reached, and the 1-year OS rate was 67.1%. Complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) were seen in 14% ( n = 7 ), 46% ( n = 23 ), 32% ( n = 16 ), and 8% ( n = 4 ) of the 50 patients, respectively. Therefore, the ORR and DCR were 60% (30/50) and 92% (46/50), respectively. The CR rate of patients with radiotherapy was higher than that without radiotherapy (25% vs. 3.8%, P = 0.031 ). The 1-year OS rate was higher in patients with radiotherapy than in patients without radiotherapy (85.9% vs. 53.2%, P = 0.020 ). The most observed AEs included anemia, decrease in white blood cell count, nausea/vomiting, and hypoproteinemia. Sintilimab-based regimens achieved good disease control and tolerance for treating advanced EC in the real world. Combined radiotherapy can improve the efficacy and deserves further study.

show abstract

Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib

Cited by 8 publications

References 15 publications

Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases

Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases

Circulating Tumor Cells in Breast Cancer Patients: A Balancing Act between Stemness, EMT Features and DNA Damage Responses

Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study

Contact Info

Product

Resources

About